Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study ...

Interferons are glycoprotein cytokines secreted by host lymphocytes in response to pathogens. Interferons activate or upregulate immune cells by interacting with receptors that activate signal ...

Department of Hepatobiliary and Pancreatic Medicine, The First Hospital of Jilin University Changchun, Changchun, Jilin, China Background: Sequential or combined treatment with nucleos(t)ide analogs ...

Introduction: The minority of the chronic hepatitis B (CHB) patients received polyethylene glycol interferon (PEG-IFN) combined with nucleotide analogs (NAs) can obtain hepatitis B surface antigen ...

The drug candidate is a pegylated human interferon lambda 1- lambda 3 chimeric protein, that acts by targeting interferon lambda receptor 1 (IL28RA or IFNLR1). It is developed based on Prositsole ...

Department of Biological Science and Technology, Center for Intelligent Drug Systems and Smart Bio-devices (IDS 2 B), National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan Department of ...

34 patients), xalnesiran 200 mg + pegylated interferon alfa-2a 180 µg (group 4; 30 patients), or NA alone (group 5; 35 patients). The primary efficacy end point was HBsAg loss at 24 weeks after ...

Having both viruses increases the risk of liver disease-related death and liver cancer, and current treatment with pegylated interferon alpha products is lengthy and not very effective ...

Results from the pegylated versus standard interferon- -2b/ribavirin combination study raise a number of issues concerning optimum dosage and duration of treatment with the pegylated formulation.

Introduction How Serious is the Problem? Treatment Options Increasing Pegylation Increases Half-Life... References ...